This is an aggregated industry headline. Read the full story at FierceBiotech →
GSK axes key cough drug candidate after phase 3 data end blockbuster hopes
GSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the drugmaker.
By FierceBiotech
· Jul 17, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Foundation Medicine has started the "Quality First" initiative to create awareness of how "not all cancer biom…
The WeekPharmaceutical Technology ↗
MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.…
The WeekSTAT News ↗
Advocates worry that excluding trans youth in some way from LGBTQ+ counseling services provided through the 98…